List view / Grid view

Articles

Immunogenicity: anticipating and avoiding issues for biopharmaceutical development

21 September 2015 | By

All biopharmaceutical products are associated with an intrinsic potential to induce immune responses in treated subjects. Regulatory agencies expect sponsors to evaluate and mitigate these risks during product development, applying a strategy that addresses product- and patient-related factors. Overall, understanding and controlling immunogenicity-related risks are attainable objectives, and approvability should…

Microfluidic technology: the next-generation drug discovery tool

21 September 2015 | By ,

Microfluidic miniaturisation, or the so-called ‘lab-on-a-chip’ concept, now encroaches on the fields of biology, medicine and pharmacology, and the nature of microfluidic technology (small volumes and high-throughput integration of fluid connections) means that it is outperforming conventional bench work. There has been an incredible need for microfluidic technology in the…

Ion channels: Small molecules versus biologics – the quest for the ideal Nav1.7 inhibitor

21 September 2015 | By ,

Ion channels modulate and control many fundamental physiological processes in various tissues and alterations in their functions give rise to a wide range of pathophysiologies, which makes them important drug targets. Indeed, for decades, drugs modulating ion channel activity have been targeted by the pharmaceutical industry. Historically, however, developing drugs…

Flow cytometry: Not just a box in the lab

21 September 2015 | By

Undoubtedly, you will have noticed the increase in the number of publications utilising flow cytometry, heard it mentioned more in meetings and probably even been targeted by several companies trying to sell you their latest cytometer. The rapidly advancing technology behind the cytometer and an increase in applications that use…

SSPC – advancing science from molecule to medicine

6 August 2015 | By Synthesis and Solid State Pharmaceutical Centre (SSPC)

Read how the Synthesis and Solid State Pharmaceutical Centre (SSPC) is positioning Ireland as a global hub for advanced pharmaceutical manufacturing...

Stem cells: maintaining hope and challenging hype

6 July 2015 | By Caroline Richards, Editor

Inspired by her attendance at ISSCR 2015, Editor of Drug Target Review, Caroline Richards, discusses stem cells and the rise of unregulated stem cell practitioners...

The importance of adequately triaging hits from HTS campaigns

19 June 2015 | By , ,

High throughput screening (HTS) continues to be employed in drug discovery as the primary source of identifying chemical starting points for drug discovery and tool compounds for chemical biology, respectively. Although small molecule drug discovery efforts have focused largely upon enzyme, receptor and ion-channel targets, there has been an increase…

Investigation of venom use in stem cell differentiation

16 June 2015 | By ,

Stem cells differentiate to form more than 200 specialised cells, including erythroid bodies, haematopoietic cells, myogenic cells, neural cells, signalling cells and structural cells, such as hepatocytes. Differentiation of stem cells triggers a number of variable changes in the cell, such as membrane potential, responsiveness to signal, metabolic activities, and…

Human pluripotent stem cell-derived cardiomyocytes in drug discovery and development

12 June 2015 | By , ,

Procedures for cardiac differentiation of human pluripotent stem cells (hPSCs) have greatly improved over the past few years. The facilitated derivation of hPSC-cardiomyocytes has enabled the thorough assessment of their physiology and manipulation of their properties. Moreover, patient-specific hPSCs generated through cellular reprogramming allow for cardiac disease modelling, discovery of…